Professor of Medicine, Boston University
Rheumatology
Dr. Robert W. Simms, MD
|
|
Give Review
Robert Simms is an expert in the field of Rheumatology. He received 4 awards: "America's Top Doctors", "Boston Magazine", "Top MD" and "Super Doctor". Robert W. Simms, MD is also a published physician. He has 67 paper published. The most recent paper is: Fibromyalgia is not a muscle disorder. Robert Simms accepts Medicare.
Publications
- A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.
- Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling.
- Antinuclear antibody-negative systemic sclerosis.
- Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Sclerod...
- Association of Interferon- and Transforming Growth Factor β-Regulated Genes and Macrophage Activation With Systemic Sclerosis-Related Progressive Lung Fibrosis.
- Immunochip analysis identifies multiple susceptibility Loci for systemic sclerosis.
- Key roles for interferon- and TGF-beta-regulated genes, and macrophage activation in progressive lung fibrosis associated with Systemic Sclerosis.
- Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry.
- Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial.
- The risk of cardiovascular Disease in systemic sclerosis: a population-based cohort study.
- Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis.
- Care of patients with scleroderma in the intensive care setting.
- B Cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
- A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type...
- Durometry for the assessment of skin Disease in systemic sclerosis.
- The role of leukotrienes in alveolitis associated with scleroderma.
- Beta 2 microglobulin serum levels and prediction of survival in AL amyloidosis.
- Cytokine directed therapy in scleroderma: rationale, current status, and the future.
- The comparative efficacy of drug therapies used for the management of corticosteroid-induced Osteoporosis: a meta-regression.
- Pulmonary hypertension and interstitial lung Disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
- Is there muscle pathology in fibromyalgia Syndrome?
- Controlled trials of therapy in fibromyalgia Syndrome.
- Bowel dysfunction in fibromyalgia Syndrome.
- Extrapulmonary thoracic restriction (hidebound chest) complicating eosinophilic fasciitis.
- The clinical significance of liver Disease in systemic lupus erythematosus.
- Relapsing polychondritis and aseptic meningitis.
- Fever, arthralgias, skin lesions, and ischemic digits in a 59-year-old man.
- High frequency of fibromyalgia in patients with Chronic fatigue seen in a primary care practice.
- Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
- Fibromyalgia is not a muscle disorder.
- A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of Arthritis.
- Established fibromyalgia Syndrome and parvovirus B19 infection.
- Fibromyalgia Syndrome: current concepts in pathophysiology, clinical features, and management.
- Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
- Symptoms mimicking neurologic disorders in fibromyalgia Syndrome.
- Scintigraphic functional hyposplenism in amyloidosis.
- Development of preliminary criteria for response to treatment in fibromyalgia Syndrome.
- Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis.
- Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation.
- Orthotopic liver transplantation for familial amyloidotic polyneuropathy.
- Liver transplantation as a treatment for familial amyloidotic polyneuropathy.
- Fibromyalgia Syndrome in patients infected with human immunodeficiency virus. The Boston City Hospital Clinical AIDS Team.
- Quality indicator set for systemic sclerosis.
- Cyclophosphamide versus placebo in scleroderma lung Disease.
- Increased frequency and compromised function of T regulatory Cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression.
- MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
- Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung Disease: results from the scleroderma lung study.
- Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival.
- Tenderness in 75 anatomic sites. Distinguishing Fibromyalgia patients from controls.
- The epidemiology of AL and AA amyloidosis.
- Lack of association between fibromyalgia Syndrome and abnormalities in muscle energy metabolism.
- Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung Disease.
- Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
- Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid ...
- Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
- Dose-intensive melphalan with blood stem Cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
- Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
- Distinct evolution of TLR-mediated dendritic Cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis.
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
- Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).
- The role of vitamin D in corticosteroid-induced Osteoporosis: a meta-analytic approach.
- Measuring Disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
- Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
- Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
- The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in p...
Schools
University Of Rochester School Of Medicine and Dentistry
North Shore Hospital
Brigham and Women39s Hospital
Boston University Med Center
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
- Trigger Point Injection
Conditions Treated
- Adhesive Capsulitis
- Ankylosing Spondylitis
- Arthritis
- Bursitis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Fallon Community Health Plan
- Harvard Pilgrim Health Care PPO
- Humana
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Neighborhood Health Plan
- Tufts Health Plans
- Tufts PPO
- UniCare
- United Healthcare
Awards
- America's Top Doctors
- Boston Magazine
- Top MD
- Super Doctor
Education
-
Boston University Medical Center -
North Shore-Long Island Jewish Health System
Hospital
-
Boston Medical Center
Drug Facts
| NPI NUMBER | 1235101429 | |
| NPPES Provider LastName | SIMMS | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 021182526 | |
| NPPES Provider State | MA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 1185.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 148.0 | |
| Percent Opioid Claims | 12.49 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235101429 |
| Last Name Of The Provider | SIMMS |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Patricia A. Fraser, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel H. Solomon, MD |
|
|
Dr. Kevin S. Wei, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara K. Tedeschi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Plenge, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Seoyoung C. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Konstantinos Loupasakis, MD |
|
|
Dr. Julia F. Charles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory R. Emkey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Chou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer M. Nashel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. I Cheng Ho, MD |
|
|
Dr. Bonnie L. Bermas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Malgorzata I. Dawiskiba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter A. Merkel, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Steven C. Vlad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David W. Gray, MD
This Doctor is OpenDoctor Recommended.
|